[Biotherapy of neuroendocrine tumors].
The somatostatin analogues have an excellent symptomatic therapeutic effect (60-90% responses in carcinoid syndrome) which permits an amelioration in the quality of life, particularly in patients with metastatic tumours. The availability of long-acting somatostatin analogues assuring stable plasma concentrations over several weeks (thanks to progressive liberation) further facilitates the use of these medications by allowing a reduction in the number of injections. Interferon also has an anti-secretory effect, albeit inferior to that of the somatostatin analogues, but potentially of interest in the case of resistance to these products.
Chanson
Philippe
P
Service d'endocrinologie et des maladies de la reproduction Centre hospitalier universitaire de Bicêtre 94275 Le Kremlin-Bicêtre. pchanson@club-internet.fr
Ducreux
Michel
M
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D019008:Drug Resistance, Neoplasm; D006728:Hormones / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use*; D018358:Neuroendocrine Tumors / Q000188:drug therapy* / Q000473:pathology; D011788:Quality of Life; D013004:Somatostatin / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D006728:Hormones; D016898:Interferon-alpha; D013004:Somatostatin
Biothérapie des tumeurs neuro-endocrines.